Research on Emerging Medical radIonuclides from the X-sections (REMIX): The Accelerator-based Production of 47Sc, 149Tb, 152Tb, 155Tb and 161Tb

G. Pupillo,U. Anselmi-Tamburini, F. Barbaro,M. Bello, S. Bortolussi,A. Boschi, M. Campostrini, L. Canton,M. P. Carante, E. Cazzola,S. Cisternino, A. Colombi, M. Colucci,L. De Dominicis,L. De Nardo,A. Duatti, A. Fontana,G. Gorgoni, F. Groppi,F. Haddad, S. Manenti,P. Martini,L. Melendez-Alafort,L. Mou, E. Nigron, V. Rigato, G. Sciacca, J. Esposito

28TH INTERNATIONAL NUCLEAR PHYSICS CONFERENCE, INPC 2022(2023)

引用 0|浏览5
暂无评分
摘要
The REMIX project is focused on the cyclotron-based production of Sc-47, Tb-149, Tb-152, Tb-155 and Tb-161 radionuclides, whose decay characteristics make them suitable for medical applications. This work will outline the main results achieved withing the REMIX collaboration, that is organized in the following Work Packages (WP): WP1. Target manufacturing (Ti-49, Ti-50 and (Gd2O3)-Gd-155) and characterization; WP2. Nuclear cross section (XS) measurements with Ti-49 and Ti-50 targets for Sc-47 production; WP3. Nuclear XS measurements with Dy-nat, Tb-159 and Eu-nat targets for Tb-xx production; WP4. Nuclear XS modeling for Sc-47 and Tb-155 production; WP5. Dosimetric calculations for Sc-47- and Tb-xx-labelled radiopharmaceuticals; WP6. Tb-155 Thick Target Yield (TTY) measurements; WP7. Apparatus design and realization for irradiation tests with the LARAMED beamline. Since the LARAMED bunkers and ancillary laboratories are currently under completion at the INFN-LNL, the nuclear XS experiments are carried out in collaboration with the GIP ARRONAX facility (Saint-Herblain, France) and the Thick Target Yield (TTY) measurements are performed at the Sacro Cuore Don Calabria hospital (SCDCh, Negrar, Verona, Italy).
更多
查看译文
关键词
emerging medical radionuclides,remix,x-sections,accelerator-based
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要